Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard | 11 October 2018

      Cochlear implants are amazing. They can vastly improve the hearing capability of people who are profoundly deaf. They work by using electrodes to stimulate nerve cells in different parts of the cochlea (the part of the inner ear which responds to sound) to provide a sensation of sound. These electrodes work in place of the sound-sensing hair cells in the cochlea, which are often damaged or absent when someone is profoundly deaf.

      Cochlear implants are amazing, but not perfect

      But cochlear implants are not perfect. They currently use electrical pulses to stimulate particular areas of the cochlea which respond to sounds of different pitches. But while there are usually over 3,000 hair cells in the inner ear, each responding to sounds at slightly different pitches, the cochlear implant has a maximum of around 20 electrodes. This means that a cochlear implant cannot separate out sounds as easily as the inner ear. In addition, the electrical signals produced by the electrodes are hard to focus, and can spill over into other regions of the inner ear. This means that the brain receives lower-quality information from the ear, and the sounds a person hears can be scrambled and hard to make sense of.

      For people that use cochlear implants, therefore, it can be difficult for them to hear in noisy environments, and to understand complex sounds like speech and music. As a result, researchers are looking for ways to overcome this limitation in the performance of cochlear implants.


      Hearing with light

      From April this year, we’ve been funding a team of researchers based at the Bionics Institute, in Melbourne, Australia, led by Dr Rachael Richardson, to work on a possible solution to this problem. We’re funding them to investigate whether light could be used to stimulate the nerve cells in the cochlea – we can focus light much more accurately than electrical pulses. Theoretically, if we could replace the electrodes in a cochlear implant with light-emitting diodes (LEDs), the light they produce could be focused enough to only stimulate a very small region of the cochlea. This would allow the implant to separate out sounds according to their pitch much more accurately, and prevent the spill-over into other areas of the cochlea (you can see this illustrated in the image). This would ultimately lead to cochlear implants which are much better able to pass on accurate information about sound to the brain.  

      Light can be focused more tightly than electrical pulses, providing clearer signals from a cochlear implant.

      Light can be focused more tightly than electrical pulses, providing clearer signals from a cochlear implant.

      Previous research has shown that we can make hearing nerve cells respond to light by introducing a gene that produces a light-sensitive protein into them (using a technique called gene therapy). Rachael and her team will be using this to investigate three exciting areas:

      How will the nerve cells respond to light?

      They will assess how well hearing nerve cells respond to light stimulation, electrical stimulation, as well as light combined with electrical stimulation. They will do this by presenting light and electrical pulses to nerve cells grown in a dish, as well as in the cochlea of mice. These cells (and mice) have been genetically modified so that the hearing nerve cells produce the light-sensitive protein, so that they can respond to light stimulation. 

      How accurate can light stimulation be?

      They will investigate how far apart two beams of light need to be, so that different hearing nerve cells along the cochlea activate completely separately from each other and there is no spill-over between them.

      Is it safe?

      They will also determine if it is possible to safely and effectively introduce the new light-sensitive gene into a hearing nerve cell’s normal genes.

      If successful, this innovative new research could greatly improve the precision of cochlear implants, allowing deaf cochlear implant users to experience more complex and accurate sound information. This step-change in cochlear implant technology could revolutionise the way that deaf people with a cochlear implant hear the world.

      Find out more

      We depend on your donations so we can fund the best hearing and tinnitus research around the world. Donate today and help us continue our vital work into hearing treatments, so that people can live life to the full again.

      You can find out more about the research we’re funding in our biomedical research section.

      If you’re interested in finding out more about our research, sign up to receive our Soundbite newsletter. It’s a monthly email, filled with the latest news about hearing and tinnitus research.

      Dr Rachael Richardson, from the Bionics Institute in Melbourne, Australia
      Dr Rachael Richardson, from the Bionics Institute in Melbourne, Australia

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Scientifically speaking

      A project based at Cincinnati Children’s Hospital in the US is using virtual reality technology to assess children’s hearing. Dr Hannah Stewart tells us how.

      By: Dr Hannah Stewart
      11 October 2018

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Scientifically speaking

      A project based at Cincinnati Children’s Hospital in the US is using virtual reality technology to assess children’s hearing. Dr Hannah Stewart tells us how.

      By: Dr Hannah Stewart
      11 October 2018

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.